Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Paclitaxel and TAK-228 in Metastatic Urothelial Carcinoma (UC) and the Impact of PI3K-mTOR Pathway Genomic Alterations

NCT03745911 is registered in ClinicalTrials.gov with Associació per a la Recerca Oncologica, Spain as lead sponsor.

NCT NCT03745911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03745911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Paclitaxel and TAK-228 in Metastatic Urothelial Carcinoma (UC) and the Impact of PI3K-mTOR Pathway Genomic Alterations
Lead sponsor
Associació per a la Recerca Oncologica, Spain
Phase
Phase 2
Overall status
Unknown status
Start date
May 4, 2018
Completion date
November 30, 2020
Enrollment
52 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial cancer